Sherlyn Lau

• Softcare Limited (HKEX: 2698, Softcare) on its initial public offering (IPO) and listing on the Main Board of the Hong Kong Stock Exchange (HKEX). The offering has raised gross proceeds of approximately HKD2.38bn (USD306.6m). Softcare develops, manufactures and sells baby and feminine hygiene products. It focuses on fast-growing emerging markets including Africa, Latin America and Central Asia.*
• the dual primary listing of Jiaxin International Resources Investment Limited (HKEX: 3858, Jiaxin International) on the Main Board of the Hong Kong Stock Exchange (HKEX) and Kazakhstan’s Astana International Exchange (AIX). The offering raised approximately HKD1.2bn (USD153m). This marks the world’s first dual primary listing on both the HKEX and AIX. Jiaxin International is a tungsten mining company focusing on the development of the Boguty tungsten mine based in Kazakhstan.*
• Guangdong Tianyu Semiconductor Co., Ltd. (HKEX: 2658, Tianyu Semiconductor) on its initial public offering (IPO) and H share listing on the Main Board of the Hong Kong Stock Exchange (HKEX). The offering raised approximately HKD1.67bn (USD214.6m). Tianyu Semiconductor is a manufacturer focusing on the self-manufactured silicon carbide (SiC) epitaxial wafers. SiC is one of the two primary third-generation semiconductor materials.*
• Qyuns Therapeutics Co., Ltd. (HKEX: 2509, Qyuns) on its initial public offering (IPO) and H share listing on the Main Board of the Hong Kong Stock Exchange (HKEX) under Chapter 18A of the Hong Kong Listing Rules. The offering raised approximately HKD239m (USD30.5m). Qyuns is a clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline and an established commercial-scale in-house manufacturing capability.*

*Denotes experience at a previous firm.